Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2005 3
2006 2
2007 1
2008 1
2009 5
2010 8
2011 9
2012 10
2013 9
2014 26
2015 43
2016 73
2017 92
2018 95
2019 87
2020 110
2021 107
2022 93
2023 76
2024 38

Text availability

Article attribute

Article type

Publication date

Search Results

774 results

Results by year

Filters applied: . Clear all
Page 1
Nonalcoholic fatty liver disease: another leap forward.
Abdelmalek MF. Abdelmalek MF. Nat Rev Gastroenterol Hepatol. 2021 Feb;18(2):85-86. doi: 10.1038/s41575-020-00406-0. Nat Rev Gastroenterol Hepatol. 2021. PMID: 33420415 Free PMC article. Review.
Primary biliary cholangitis.
Lleo A, Wang GQ, Gershwin ME, Hirschfield GM. Lleo A, et al. Lancet. 2020 Dec 12;396(10266):1915-1926. doi: 10.1016/S0140-6736(20)31607-X. Lancet. 2020. PMID: 33308474 Review.
For patients who do not respond sufficiently, or patients with ursodeoxycholic acid intolerance, conditionally licensed add-on therapy is with the FXR (NR1H4) agonist, obeticholic acid. Off-label therapy is recognised as an alternative, notably with the pan-PPAR ago …
For patients who do not respond sufficiently, or patients with ursodeoxycholic acid intolerance, conditionally licensed add-on therapy is wi …
Primary biliary cholangitis: pathogenesis and therapeutic opportunities.
Gulamhusein AF, Hirschfield GM. Gulamhusein AF, et al. Nat Rev Gastroenterol Hepatol. 2020 Feb;17(2):93-110. doi: 10.1038/s41575-019-0226-7. Epub 2019 Dec 9. Nat Rev Gastroenterol Hepatol. 2020. PMID: 31819247 Review.
Substantial progress has been made in patient risk stratification with the goal of personalized care, including early adoption of next-generation therapy with licensed use of obeticholic acid or off-label fibrate derivatives for those with insufficient benefit from …
Substantial progress has been made in patient risk stratification with the goal of personalized care, including early adoption of next-gener …
Evolving Role for Pharmacotherapy in NAFLD/NASH.
Attia SL, Softic S, Mouzaki M. Attia SL, et al. Clin Transl Sci. 2021 Jan;14(1):11-19. doi: 10.1111/cts.12839. Epub 2020 Aug 25. Clin Transl Sci. 2021. PMID: 32583961 Free PMC article. Review.
Three drugs have gone on to phase III trials for which results are available. Of those, obeticholic acid is the single agent that demonstrates promise according to the interim analyses of the REGENERATE trial. Obeticholic acid showed reduction of fibro …
Three drugs have gone on to phase III trials for which results are available. Of those, obeticholic acid is the single agent t …
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Younossi ZM, et al. Lancet. 2019 Dec 14;394(10215):2184-2196. doi: 10.1016/S0140-6736(19)33041-7. Epub 2019 Dec 5. Lancet. 2019. PMID: 31813633 Free article. Clinical Trial.
The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0.045), and 71 (23%) in the obeticholic acid 25 mg group (p=0.0002). The NASH resolution endpoint was not met (25 …
The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 …
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer.
Sun L, Cai J, Gonzalez FJ. Sun L, et al. Nat Rev Gastroenterol Hepatol. 2021 May;18(5):335-347. doi: 10.1038/s41575-020-00404-2. Epub 2021 Feb 10. Nat Rev Gastroenterol Hepatol. 2021. PMID: 33568795 Review.
FXR can influence glucose and lipid homeostasis. Hepatic FXR activation by obeticholic acid is currently used to treat primary biliary cholangitis. Late-stage clinical trials investigating the use of obeticholic acid in the treatment of nonalcoholic st …
FXR can influence glucose and lipid homeostasis. Hepatic FXR activation by obeticholic acid is currently used to treat primary …
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease.
Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LW, Siersema PD, Schipper ME, Danese S, Penna G, Laverny G, Adorini L, Moschetta A, van Mil SW. Gadaleta RM, et al. Gut. 2011 Apr;60(4):463-72. doi: 10.1136/gut.2010.212159. Epub 2011 Jan 17. Gut. 2011. PMID: 21242261
METHODS: Colitis was induced in wild-type (WT) and Fxr-null mice using dextran sodium sulfate, and in WT mice using trinitrobenzenesulfonic acid. Mice were treated with vehicle or the FXR agonist INT-747, and colitis symptoms were assessed daily. Epithelial permeabi …
METHODS: Colitis was induced in wild-type (WT) and Fxr-null mice using dextran sodium sulfate, and in WT mice using trinitrobenzenesulfonic …
Microbiota-induced lipid peroxidation impairs obeticholic acid-mediated antifibrotic effect towards nonalcoholic steatohepatitis in mice.
Zhuge A, Li S, Yuan Y, Han S, Xia J, Wang Q, Wang S, Lou P, Li B, Li L. Zhuge A, et al. Redox Biol. 2023 Feb;59:102582. doi: 10.1016/j.redox.2022.102582. Epub 2022 Dec 22. Redox Biol. 2023. PMID: 36584600 Free PMC article.
Obeticholic acid (OCA) has been examined to treat non-alcoholic steatohepatitis (NASH), but has unsatisfactory antifibrotic effect and deficient responsive rate in recent phase III clinical trial. ...
Obeticholic acid (OCA) has been examined to treat non-alcoholic steatohepatitis (NASH), but has unsatisfactory antifibrotic ef …
Obeticholic Acid.
[No authors listed] [No authors listed] 2019 Dec 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2019 Dec 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644113 Free Books & Documents. Review.
Obeticholic acid (OCA) is a synthetically modified bile acid and potent agonist of the farnesoid X nuclear receptor (FXR) that is used to treat liver diseases including primary biliary cholangitis. Obeticholic acid has not been linked to elevations in …
Obeticholic acid (OCA) is a synthetically modified bile acid and potent agonist of the farnesoid X nuclear receptor (FXR) that …
SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.
Zhou J, Cui S, He Q, Guo Y, Pan X, Zhang P, Huang N, Ge C, Wang G, Gonzalez FJ, Wang H, Hao H. Zhou J, et al. Nat Commun. 2020 Jan 13;11(1):240. doi: 10.1038/s41467-019-14138-6. Nat Commun. 2020. PMID: 31932588 Free PMC article.
Here we report that prophylactic but not therapeutic administration of obeticholic acid (OCA) prevents hepatic stellate cell (HSC) activation and fibrogenesis. ...
Here we report that prophylactic but not therapeutic administration of obeticholic acid (OCA) prevents hepatic stellate cell ( …
774 results